Interferon alfa-2a: Difference between revisions
No edit summary |
|||
| Line 10: | Line 10: | ||
==US Brand Names== | ==US Brand Names== | ||
ROFERON-A<sup>®</sup> | ROFERON-A<sup>®</sup>,PEGASYS<sup>®</sup>,GUNA-INF ALPHA<sup>®</sup> | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
Revision as of 00:02, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.
Category
Antiviral
US Brand Names
ROFERON-A®,PEGASYS®,GUNA-INF ALPHA®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages